

**CENTER FOR DRUG  
EVALUATION AND  
RESEARCH**

**APPLICATION NUMBER:**

**75-761**

**MICROBIOLOGY REVIEW(S)**

OFFICE OF GENERIC DRUGS, HFD-640  
Microbiology Review #1  
October 23, 2000

9

- A. 1. ANDA 75-761  
APPLICANT: American Pharmaceutical Partners, Inc.
2. PRODUCT NAME: Amiodarone Hydrochloride Injection
3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: 50 mg/mL; I/V  
3-mL in 3-mL vials
4. METHOD(S) OF STERILIZATION: \_\_\_\_\_
5. PHARMACOLOGICAL CATEGORY: Anti-arrhythmic
- B. 1. DATE OF INITIAL SUBMISSION: December 22, 1999  
Subject of this Review (Received December 23, 1999)
2. DATE OF AMENDMENT: New Correspondence  
February 10, 2000  
Subject of this Review (Received February 11, 2000)
3. RELATED DOCUMENTS: None
4. ASSIGNED FOR REVIEW: October 13, 2000
- C. REMARKS: The subject drug product is manufactured by American Pharmaceutical Partners, Inc. at its manufacturing facility located at 3159 Staley Rd., New York. The subject drug is \_\_\_\_\_ in 3-mL glass vials in \_\_\_\_\_
- D. CONCLUSIONS: The submission is **not recommended** for approval on the basis of sterility assurance. Specific comments are provided in "E. Review Notes" and "Microbiology Comments To Be Provided To The Applicant" found at the end of this review. The above deficiencies represent a Fax amendment.

Nrapendra Nath 10/30/00  
Nrapendra Nath, Ph. D.

QA  
10/30/00

CC: Original ANDA  
Duplicate ANDA  
Division Copy  
Field Copy  
Drafted by N. Nath, HFD 600; V:\microrev\75761.doc  
Initialed by A. High

E. REVIEW NOTES:

1. General Drug and Processing Descriptions. The applicant has proposed to manufacture Amiodarone Hydrochloride Injection as a generic equivalent of Cordarone® manufactured by Wyeth-Ayerst Co. The formulation of the drug product is as follows:

Ingredient	Per mL
Amiodarone HCl EP	50 mg
Polysorbate 80 NF	100 mg
Benzyl Alcohol NF	20.2 mg
WFI	QS

pH is adjusted to between 3.2 and 4.2.

The Amiodarone Hydrochloride is \_\_\_\_\_

The subject drug product is filled as a single dose in 3-mL glass vials. The recommended storage conditions for the subject drug product are 15-25°C protected from light. A 24-month expiration dating for the subject drug product is proposed by the applicant subject to the results of the stability studies.

The sources of containers and closures used to fill the subject drug product are summarized below (volume 1.2, page 344):

Container/Closure	
<b>Vials-</b> 3-mL Type I USP Glass,	
<b>Stoppers-</b> 13 mm	
<b>Seals-</b> 13 mm Flip-cap Aluminum, coated	

2. Facility and Environmental Control Descriptions. All aspects of the manufacturing and QC of the subject drug product, except sterility and endotoxin testing, will be performed at the following address (volume 1.1, page 160):

American Pharmaceutical Partners, Inc.  
3159 Staley Road  
Grand Island, NY 14072

The sterility and endotoxin testing will be performed at another facility of the American Pharmaceutical Partners located at 2045 Cornell Avenue, Melrose Park, IL 60160.

to determine the chemical purity of the subject drug product.

The main Manufacturing Facility consists of a

**Redacted** 12

**Page(s) of trade**

**secret and /or**

**confidential**

**commercial**

**information**

OFFICE OF GENERIC DRUGS, HFD-640  
Microbiology Review #2  
June 8, 2001

A. 1. ANDA 75-761

APPLICANT: American Pharmaceutical Partners, Inc.

2. PRODUCT NAME: Amiodarone Hydrochloride Injection

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: 50 mg/mL; I/V  
3-mL in 3-mL vials

4. METHOD(S) OF STERILIZATION: \_\_\_\_\_

5. PHARMACOLOGICAL CATEGORY: Anti-arrhythmic

B. 1. DATE OF INITIAL SUBMISSION: December 22, 1999

2. DATE OF AMENDMENT: November 10, 2000  
**Subject of this Review (Received November 14, 2000)**

3. RELATED DOCUMENTS: None

4. ASSIGNED FOR REVIEW: June 8, 2001

C. REMARKS: The subject amendment provides for the response to microbiology deficiencies in the correspondence dated November 1, 2000.

D. CONCLUSIONS: The submission is **not recommended** for approval on the basis of sterility assurance. Specific comments are provided in "E. Review Notes" and "Microbiology Comments To Be Provided To The Applicant" found at the end of this review. The above deficiencies represent a **minor** amendment.

Nrapendra Nath 6/7/01  
Nrapendra Nath, Ph. D.

(CN) 6/8/01

CC: Original ANDA  
Duplicate ANDA  
Division Copy  
Field Copy  
Drafted by N. Nath, HFD 600; V:\microrev\75761a1.doc  
Initialed by A. High

**Redacted** 4

**Page(s) of trade**

**secret and /or**

**confidential**

**commercial**

**information**

OFFICE OF GENERIC DRUGS, HFD-640  
Microbiology Review #3  
June 20, 2001

- A. 1. ANDA 75-761  
APPLICANT: American Pharmaceutical Partners, Inc.
2. PRODUCT NAME: Amiodarone Hydrochloride Injection
3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: 50 mg/mL; I/V  
3-mL in 3-mL vials
4. METHOD(S) OF STERILIZATION: \_\_\_\_\_
5. PHARMACOLOGICAL CATEGORY: Anti-arrhythmic
- B. 1. DATE OF INITIAL SUBMISSION: December 22, 1999
2. DATE OF AMENDMENT: June 19, 2001  
**Subject of this Review (Received June 20, 2001)**
3. RELATED DOCUMENTS: None
4. ASSIGNED FOR REVIEW: June 20, 2001
- 5.
- C. REMARKS: The subject amendment provides for the response to microbiology deficiencies in the correspondence dated June 12, 2001.
- D. CONCLUSIONS: The submission is **recommended** for approval on the basis of sterility assurance. Specific comments are provided in "E. Review Notes".

*Nrapendra Nath 6/25/01*  
\_\_\_\_\_  
Nrapendra Nath, Ph. D.

*(Signature)*  
6/25/01

CC: Original ANDA  
Duplicate ANDA  
Division Copy  
Field Copy  
Drafted by N. Nath, HFD 600; V:\microrev\75761a2.doc  
Initialed by A. High

**Redacted** \_\_\_\_\_

**Page(s) of trade**

**secret and /or**

**confidential**

**commercial**

**information**